Loncar Cancer Immunotherapy ETF (CNCR), which invests in companies that produces drugs that modify body’s immune response to treat cancer, is set to roll out on Wednesday in the US. “A goal is to take biotechnology and break it down into one of its individual components— like cancer immunotherapy— that people are specifically interested in”, said a biotech investor. 